TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16048650
Drug: ciprofloxacin 250
Normalized name: ciprofloxacin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ciprofloxacin 250 mg twice daily for 3 days
Study: 16048650
Drug: nitrofurantoin 100
Normalized name: nitrofurantoin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nitrofurantoin 100 mg twice daily for 7 days
Study: 7541860
Drug: 560 mg
Normalized name: spinosad 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 560 mg estramustine phosphate daily for 6 weeks preoperatively
Study: 849020
Drug: Metrifonate (Bilarcil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metrifonate (Bilarcil Bayer AG) at a dose rate of 7.5 mg/kg once per fortnight for three doses during therapy stage and four-weekly during prophylaxis stage.
Study: 12712083
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution placebo
Study: 13679971
Drug: Grouped dosage
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grouped dosage of immunotherapy
Study: 13679971
Drug: Conventional dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dosage of immunotherapy
Study: 2065403
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron supplementation every day for three months (G1)
Study: 2065403
Drug: Daily iron
Normalized name: Walgreens Multivitamin One Daily Iron-Free Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily iron supplementation for anaemic infants (G3)
Study: 31036058
Drug: Integrative improvisational
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrative improvisational music therapy (IIMT) alone
Study: 31036058
Drug: Integrative improvisational
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrative improvisational music therapy (IIMT) with home‐based listening (LH)
Study: 31036058
Drug: Integrative improvisational
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrative improvisational music therapy (IIMT) with resonance frequency breathing (RFB)
Study: 31036058
Drug: Integrative improvisational
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrative improvisational music therapy (IIMT) with both enhancements (LH and RFB)
Study: 22732975
Drug: Lactobacillus plantarum
Normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus plantarum CECT 7315/7316 (5*10^9 cfu/day) in 20 g powdered skim milk
Study: 22732975
Drug: Lactobacillus plantarum
Normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus plantarum CECT 7315/7316 (5*10^8 cfu/day) in 20 g powdered skim milk
Study: 22732975
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 g powdered skim milk)
Study: 24491070
Drug: Assessment-only (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment-only (treatment as usual)
Study: 19650856
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of erythropoietic stimulating agents and/or intravenous iron
Study: 16814449
Drug: Oral continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral continuous combined therapy (Group A, n = 31)
Study: 16814449
Drug: Transdermal sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal sequential hormone replacement therapy (Group B, n = 30)
Study: 12003685
Drug: Pharmacologic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic treatment with antidepressants for patients with COPD and depression
Study: 10092716
Drug: Lidocaine iontophoresis
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine iontophoresis (1 mL of 2% lidocaine with 1:100,000 epinephrine)
Study: 10092716
Drug: Control (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (1 mL of 0.9% saline solution with 1:100,000 epinephrine)
Study: 2256875
Drug: Phenytoin (anticonvulsant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenytoin (anticonvulsant dose)
Study: 7362955
Drug: Single preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single preoperative dose of cotrimoxazole and metronidazole
Study: 7362955
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of cotrimoxazole and metronidazole for 5 days
Study: 7362955
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose group
Study: 7362955
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses group
Study: 31512832
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment after tooth extraction (Control group)
Study: 11716207
Drug: Formoterol (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol (9 microg per inhalation, total cumulative dose of 27 microg)
Study: 3297895
Drug: Diethylamine persilate
Normalized name: diethylamine salicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylamine persilate (DAP) 1.5 g/day
Study: 3297895
Drug: Diethylamine persilate
Normalized name: diethylamine salicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylamine persilate (DAP) 2.5 g/day
Study: 3297895
Drug: Diethylamine persilate
Normalized name: diethylamine salicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diethylamine persilate (DAP) 0.5 g/day
Study: 27565118
Drug: Improved Treatment
Normalized name: Hybolin-Improved
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved Treatment as Usual (iTAU)
Study: 22962030
Drug: Sequential add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential add-on treatment
Study: 23117107
Drug: Iyengar yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iyengar yoga program (9-week, weekly 90-minute classes)
Study: 15086924
Drug: Calcium supplement
Normalized name: Calcium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplement taken with meal (1 g of calcium carbonate, 3 times/day)
Study: 15086924
Drug: Calcium supplement
Normalized name: Calcium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplement taken at bedtime (3 g/day of calcium carbonate)
Study: 7502689
Drug: Ethinylestradiol 20
Normalized name: Ethinylestradiol 20 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethinylestradiol 20 micrograms/day + calcium 500 mg/day
Study: 2091186
Drug: Electrolyte‐polyethylene glycol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrolyte‐polyethylene glycol solution (SE‐PEG)
Study: 2091186
Drug: Standard bowel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard bowel preparation (SBP)
Study: 28237552
Drug: Traditional speech
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional speech therapy
Study: 15096071
Drug: Venlafaxine, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine, 100 to 200 mg/day for 12 months
Study: 11774146
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine solution via an infusion pump (2 mL each hour for 48 hours)
Study: 11774146
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution via an infusion pump (2 mL each hour for 48 hours)
Study: 11477812
Drug: Buyang Huanwu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buyang Huanwu Decoction (BHD) in Chinese medicine group (CMG)
Study: 11477812
Drug: Hydroxyethyl starch
Normalized name: Hydroxyethyl starch
DrugBank: Hydroxyethyl Starch (DB09106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl starch injection and enteric coated aspirin tablets in western medicine group (WMG)
Study: 7650234
Drug: Lidocaine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (200 mg) plus adrenalin (1:200,000)
Study: 26892922
Drug: Modafinil (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (400 mg/day for 26 days, then 300 mg/day for 30 days, and 200 mg/day for 31 days)
Study: 21073082
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Gentamycin 80 mg IV (immediately after spinal anesthesia)
Study: 21073082
Drug: Extended use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended use of Amoxicillin, Chloramphenicol or Cotrimexazole (postoperatively)
Study: 21073082
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Gentamycin 80 mg IV
Study: 21073082
Drug: Extended use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended use of Amoxicillin, Chloramphenicol or Cotrimexazole
Study: 17981377
Drug: Purified duck
Normalized name: Duck
DrugBank: Duck (DB10610)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified duck embryo vaccine (PDEV, Vaxirab)
Study: 17981377
Drug: Purified duck
Normalized name: Duck
DrugBank: Duck (DB10610)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified duck embryo vaccine (Lyssavac)
Study: 7859239
Drug: Sustained-release Uni-Dur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release Uni-Dur 600-mg theophylline tablet to fasting subjects
Study: 7859239
Drug: Sustained-release Uni-Dur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release Uni-Dur 600-mg tablet after a high-fat meal
Study: 7859239
Drug: Sustained-release Uni-Dur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release Uni-Dur 600-mg dose administered as two half tablets to fasting subjects
Study: 7859239
Drug: Sustained-release Uni-Dur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release Uni-Dur 400-mg tablet to fasting subjects
Study: 7859239
Drug: Immediate-release theophylline
Normalized name: theophylline Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release theophylline (Slo-Phyllin) 5 x 100 mg to fasting subjects
Study: 7859239
Drug: Sustained-release Uni-Dur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release Uni-Dur 600-mg fasting treatment
Study: 7859239
Drug: Sustained-release Uni-Dur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release Uni-Dur 400-mg treatment
Study: 2570730
Drug: famotidine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine (40 mg at bedtime)
Study: 28222072
Drug: Central re-testing
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Central re-testing of receptor status
Study: 26130251
Drug: S-Adenosylmethionine (SAMe)
Normalized name: S-adenosylmethionine
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-Adenosylmethionine (SAMe) 2.4 g/d for 24 weeks
Study: 24277402
Drug: Enteral plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral plus parenteral nutrition (EN+PN)
Study: 21615968
Drug: GP management
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP management with adjunctive counselling (CBT)
Study: 21615968
Drug: GP management
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP management with adjunctive counselling (CBT) delivered by postnatal nurses or psychologists
Study: 12752349
Drug: PAC (pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAC (pantoprazole 40 mg, clarithromycin 500 mg, amoxicillin 1000 mg)
Study: 12752349
Drug: PAM (pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAM (pantoprazole 40 mg, amoxicillin 1000 mg, metronidazole 500 mg)
Study: 8820890
Drug: 22.2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22.2 g dibasic calcium phosphate (DCP)
Study: 3495089
Drug: Induction 2
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction 2 mg kg‐1, infusion rate 9 mg kg‐1 h‐1 (Group 1)
Study: 3495089
Drug: Induction 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction 2.5 mg kg‐1, infusion rate 12 mg kg‐1 h‐1 (Group 2)
Study: 3495089
Drug: Induction 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction 2.5 mg kg‐1, infusion rate 9 mg kg‐1 (Group 3)
Study: 25496482
Drug: Avoidance plan
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Avoidance plan (radiotherapy optimized to minimize dose to functional lung)
Study: 18354721
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic and steroid lumbar facet joint nerve blocks
Study: 10494113
Drug: Combination training
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination training (both pelvic floor muscle training and bladder training)
Study: 368354
Drug: Amantadine hydrochloride
Normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine hydrochloride 200 mg daily
Study: 22008819
Drug: HRV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRV vaccine (Rotarix™)
Study: 11385189
Drug: Transdermal estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estrogen therapy (TET)
Study: 9092956
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) at target dosages of 200-1,000 mg daily
Study: 1623901
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of 6-mercaptopurine (30 mg/m2)
Study: 1623901
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 6-mercaptopurine (87.5 mg/m2)
Study: 1623901
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of 6-mercaptopurine
Study: 30864472
Drug: Sequential IPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential IPC for 10 minutes
Study: 30864472
Drug: Sequential IPC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential IPC compared to Single-compartment IPC
Study: 15172083
Drug: Exercise three‐times
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise three‐times weekly over 12 weeks
Study: 15172083
Drug: Oral oestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oestradiol therapy for 12 weeks
Study: 12352236
Drug: 0.4 percent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 percent nitroglycerin ointment applied twice or three times per day
Study: 9815340
Drug: Scopolamine Transdermal
Normalized name: scopolamine Transdermal System
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Scopolamine Transdermal Therapeutic System (TTS)
Study: 26643558
Drug: Routine antenatal
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine antenatal and postnatal home-based care plus screening and treatment for abnormal vaginal flora (AVF) and urinary tract infection (UTI).
Study: 18637554
Drug: Intralesional steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional steroid (diluted Triamcinolone acetonide)
Study: 18637554
Drug: Silicone-gel sheeting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone-gel sheeting
Study: 12660407
Drug: D-ribose (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-ribose (10 g/d for 5 d)
Study: 12660407
Drug: Dextrose placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose placebo (5 g, twice daily)
Study: 1838693
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg cilazapril
Study: 1279292
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg cilazapril + 0.5 mg cyclopenthiazide (CPTZ)
Study: 1279292
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg cilazapril + 0.5 mg CPTZ
Study: 1279292
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg cilazapril alone
Study: 2988158
Drug: suloctidil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: suloctidil (200 mg t.i.d.)
Study: 22083263
Drug: Right half‐field
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right half‐field patch treatment (n=10) for approximately 8 hours a day for 15 consecutive days
Study: 20395128
Drug: Carboplatin AUC
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin AUC 7 every 3 weeks followed by concurrent paclitaxel 175 mg/m2 (day 1) and gemcitabine 1000 mg/m2 (days 1 and 8) every 3 weeks
Study: 20395128
Drug: Sequential schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential schedule with weekly paclitaxel
Study: 16037481
Drug: Programa de
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programa de Entrenamiento para el Desarrollo de Aptitudes para Latinos (PEDAL) group therapy
Study: 10567776
Drug: Isoniazid (INH,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid (INH, 300 mg once daily) plus sulphadoxine-pyrimethamine (S, 500 mg/P, 25 mg once weekly)
Study: 7867175
Drug: Transdermal nitroglycerin
Normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitroglycerin patches
Study: 428710
Drug: Chenodeoxycholic acid
Normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodeoxycholic acid (CDCA), 750 mg/day during weight maintenance (1st month) and weight reduction (2nd month)
Study: 428710
Drug: Bile acid
Normalized name: Bile acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bile acid preparations (CDCA and Bilron) administered randomly during weight reduction
Study: 22111802
Drug: standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard care therapy over seven-days a week
Study: 22111802
Drug: group circuit
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: group circuit class therapy over five-days a week
Study: 22111802
Drug: usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: usual care therapy over five-days a week
Study: 18154473
Drug: Nelfinavir 1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir 1250 mg every 12 hours for 4 days
Study: 18154473
Drug: Nelfinavir 1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir 1250 mg every 12 hours and omeprazole 40 mg every 24 hours for 4 days
Study: 18074761
Drug: Mistletoe extracts
Normalized name: MISTLETOE EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mistletoe extracts Iscador (therapy suggested by attending physician)
Study: 18074761
Drug: Mistletoe extracts
Normalized name: MISTLETOE EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mistletoe extracts Iscador (therapy)
Study: 10703459
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (HP, HC, HF, NS)
Study: 2580155
Drug: Atenolol (cumulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (cumulative doses of 1-8 mg)
Study: 2580155
Drug: Acebutolol (cumulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (cumulative doses of 10-80 mg)
Study: 27958381
Drug: Buprenorphine/naloxone (Suboxone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone (Suboxone) treatment
Study: 24733277
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care (CC) intervention for depression and anxiety disorders (n=92)
Study: 22445052
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy intervention
Study: 18612787
Drug: DDD‐FP (5‐FU,
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDD‐FP (5‐FU, 320 mg/m² daily for 21 days; CDDP, 3.5 mg/m² daily for 21 days) followed by oral 5‐FU (200 mg/body daily for 2 years)
Study: 18612787
Drug: Oral 5‐FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5‐FU therapy (200 mg/body daily for 2 years)
Study: 12052597
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (100 microg every 3-4 hours, with possible increase to 200 microg)
Study: 10672723
Drug: Amizon (anti-inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amizon (anti-inflammatory interferon-inducing drug)
Study: 8754965
Drug: Systemic steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic steroids (prednisone)
Study: 8754965
Drug: Inhaled steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled steroids in typical dose
Study: 1654753
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 0.5% bupivacaine (pH, 5.58 +/‐ 0.12)
Study: 1654753
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL of 0.5% bupivacaine + 0.6 mL of 1.4% bicarbonate (pH, 6.53 +/‐ 0.06)
Study: 7046412
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (150 mg/m2 daily in three divided doses)
Study: 3511184
Drug: Tamoxifen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (10 mg twice daily)
Study: 24533507
Drug: Topical valproic
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical valproic acid (sodium valproate, 8.3%)
Study: 17972591
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid and as-needed beta-agonist
Study: 17972591
Drug: Dongchong xiacao
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dongchong xiacao capsule plus inhaled corticosteroid and as-needed beta-agonist
Study: 14760514
Drug: Lecithin (1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lecithin (1.6 g/day)
Study: 14760514
Drug: Carnitine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carnitine (500 mg/day)
Study: 7805564
Drug: Hyperfractionated irradiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated irradiation (HF) with 1.15‐1.25Gy per fraction, twice daily, total doses of 69.6 +/- 2.1Gy
Study: 7805564
Drug: Conventional irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional irradiation (CF) with 1.8‐2.0Gy per fraction, once a day, total doses of 63.9 +/- 1.1Gy
Study: 31074205
Drug: Canagliflozin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin (100 mg/day)
Study: 30241913
Drug: Manual lymph
Normalized name: Bos taurus lymph preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual lymph drainage (MLD) in addition to information and exercise therapy